Global Hunter Initiates Coverage of MediciNova with Speculative Buy and PT of $4

Global Hunter initiated coverage of MediciNova MNOV with a Speculative Buy rating and a price target of $4. In a research report published today, Global Hunter states, "Our Speculative Buy rating is based on data to date, near-term milestones, attractive valuation and uncertainties around the outcome of the Phase IIb MN-221 study. Our $4 fair value estimate is based the average value from a pipeline valuation analysis, which only includes value from MN-221 in the asthma indication, and discounted cash flow (DCF) analyses that examine free cash flow through 2018. Downside to our fair value estimate could occur with negative MN-221 efficacy and safety data and the inability to partner the drug." In today's trading, MediciNova added 0.38% to its value and is currently trading around $2.35.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsGlobal Huntermedicinova
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!